A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Public ClinicalTrials.gov record NCT03345979. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation
Study identification
- NCT ID
- NCT03345979
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alkermes, Inc.
- Industry
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- Aripiprazole Lauroxil Combination Product
- Paliperidone Palmitate Drug
Combination Product · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2017
- Primary completion
- Mar 11, 2019
- Completion
- Mar 11, 2019
- Last update posted
- Aug 10, 2020
2017 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Little Rock | Arkansas | 72211 | — |
| Alkermes Investigational Site | Rogers | Arkansas | 72758 | — |
| Alkermes Investigational Site | Cerritos | California | 90703 | — |
| Alkermes Investigational Site | Culver City | California | 90230 | — |
| Alkermes Investigational Site | Garden Grove | California | 92845 | — |
| Alkermes Investigational Site | Lemon Grove | California | 91945 | — |
| Alkermes Investigational Site | Hialeah | Florida | 33012 | — |
| Alkermes Investigational Site | Chicago | Illinois | 60640 | — |
| Alkermes Investigational Site | Hoffman Estates | Illinois | 60169 | — |
| Alkermes Investigational Site | Flowood | Mississippi | 39232 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63141 | — |
| Alkermes Investigational Site | Las Vegas | Nevada | 89102 | — |
| Alkermes Investigational Site | Berlin | New Jersey | 08009 | — |
| Alkermes Investigational Site | Austin | Texas | 78754 | — |
| Alkermes Investigational Site | Garland | Texas | 75042 | — |
| Alkermes Investigational Site | Richardson | Texas | 75080 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03345979, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 10, 2020 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03345979 live on ClinicalTrials.gov.